Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ondansetron · 1 trial · 1 indication
Measured at 12 weeks post randomisation and defined, as recommended by the FDA, as patient being a weekly responder for BOTH pain intensity AND stool consistency for at least 6 weeks in the 12 week treatment period.
| Arm | Type | Description |
|---|---|---|
| Ondansetron | EXPERIMENTAL | Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms. |
| Placebo | PLACEBO_COMPARATOR | Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms. |
| Name | Type | Description |
|---|---|---|
| Ondansetron | DRUG | Ondansetron is a highly selective receptor antagonist (5-HT3RA) |
Inclusion Criteria: 1. Written (signed and dated) informed consent. 2. Considered fit for study participation. 3. Meeting Rome IV criteria for IBS-D 4. Aged ≥ 18 years 5. Undergone standardised workup to exclude the following alternative diagnoses: 1. Microscopic colitis (colonoscopy or flexibl...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 3 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | - | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | N/A | Undisclosed |
Ondansetron is being studied for the treatment of Irritable Bowel Syndrome (IBS), specifically in a Phase 3 clinical trial. It is a small molecule being developed by National Healthcare Corp. for this gastrointestinal condition.
Ondansetron targets the serotonin 5-HT3 receptor. By blocking this receptor, it may help manage symptoms of Irritable Bowel Syndrome (IBS). The drug is currently in Phase 3 clinical development for this indication.
Ondansetron is being developed by National Healthcare Corp. (ticker: NHC). The company is conducting a Phase 3 clinical trial for the drug in Irritable Bowel Syndrome (IBS).
Ondansetron is in Phase 3 clinical development for Irritable Bowel Syndrome (IBS). It is an investigational drug, and the Phase 3 trial has been completed. The drug is not yet approved for this indication.
Ondansetron has one completed Phase 3 trial, NCT03555188, titled 'TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial'. This randomized, double-blind, placebo-controlled study enrolled 80 participants in the United Kingdom.
Ondansetron is the generic name for the drug also known as Zofran. In the context of Irritable Bowel Syndrome (IBS), it is being studied under the name Ondansetron in a Phase 3 clinical trial by National Healthcare Corp.